Detalle Publicación


First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with Y-90-ibritumomab-tiuxetan in patients with mantle cell lymphoma

Autores: Arranz, R. (Autor de correspondencia); García-Noblejas, A.; Grande García, Carlos; Cannata-Ortiz, J.; Sánchez, J. J.; García-Marco, J. A.; Aláez, C.; Pérez Calvo, Javier; Martínez-Sánchez, P.; Sánchez-González, B.; Canales, M. A.; Conde, E.; Martín, A.; Arranz, E.; Terol, M. J; Salar, A.; Caballero, D.
Título de la revista: HAEMATOLOGICA
ISSN: 0390-6078
Volumen: 98
Número: 10
Páginas: 1563 - 1570
Fecha de publicación: 2013
The prognosis for fit patients with mantle cell lymphoma has improved with intensive strategies. Currently, the role of maintenance/consolidation approaches is being tested as relapses continue to appear. In this trial we evaluated the feasibility, safety and efficacy of rituximab-hyperCVAD alternating with rituximab-methotrexatecytarabine followed by consolidation with Y-90-ibritumomab tiuxetan. Patients received six cycles followed by a single dose of Y-90-ibritumomab tiuxetan. Thirty patients were enrolled; their median age was 59 years. Twenty-four patients finished the induction treatment, 23 achieved complete remission (77%, 95% confidence interval 6093) and one patient had progressive disease (3%). Eighteen patients (60%), all in complete remission, received consolidation therapy. In the intent-to-treat population, failure-free, progression-free and overall survival rates at 4 years were 40% (95% confidence interval 20.4-59.6), 52% (95% confidence interval 32.4-71.6) and 81% (95% confidence interval 67.28-94.72), respectively. For patients who received consolidation, failure-free and overall survival rates were 55% (95% confidence interval 31.48-78.52) and 87% (95% confidence interval 70-100), respectively. Hematologic toxicity was significant during induction and responsible for one death (3.3%). After consolidation, grade 3-4 neutropenia and thrombocytopenia were observed in 72% and 83% of patients, with a median duration of 5 and 12 weeks, respectively. Six (20%) patients died, three due to secondary malignancies (myelodysplastic syndrome and bladder and rectum carcinomas). In conclusion, in our experience, rituximab-hyperCVAD alternated with rituximab-methotrexate-cytarabine and followed by consolidation with Y-90-ibritumomab tiuxetan was efficacious although less feasible than expected. The unacceptable toxicity observed, especially secondary malignancies, advise against the use of this strategy. Trial registration: identifier: NCT2005-004400-37